RNA-based Therapeutics and Vaccines

RNA-based Therapeutics and Vaccines

Global RNA-based Therapeutics and Vaccines Market to Reach $499 Million by 2027

Amid the COVID-19 crisis, the global market for RNA-based Therapeutics and Vaccines estimated at US$14.7 Million in the year 2020, is projected to reach a revised size of US$499 Million by 2027, growing at aCAGR of 65.5% over the period 2020-2027. RNA-based Therapeutics, one of the segments analyzed in the report, is projected to record 68.1% CAGR and reach US$372.5 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the RNA-based Vaccines segment is readjusted to a revised 59.2% CAGR for the next 7-year period.

The U.S. Market is Estimated at $4.5 Million, While China is Forecast to Grow at 62% CAGR

The RNA-based Therapeutics and Vaccines market in the U.S. is estimated at US$4.5 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$76.6 Million by the year 2027 trailing a CAGR of 62% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 59.2% and 55.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 43.7% CAGR.

Select Competitors (Total 41 Featured) -

• Alnylam Pharmaceuticals, Inc.
• Arbutus Biopharma Corporation
• Arrowhead Pharmaceuticals, Inc.
• BioNTech AG
• CureVac AG
• Dicerna Pharmaceuticals, Inc.
• Marina Biotech, Inc.
• miRagen Therapeutics, Inc.
• Moderna, Inc.
• Quark Pharmaceuticals, Inc.
• Regulus Therapeutics, Inc.
• Sylentis S.A.

Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.